View in EDS PDF Full Text

Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.

Saved in:
Bibliographic Details
Title: Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.
Authors: Kinsella JP (AUTHOR), Walsh WF (AUTHOR), Bose CL (AUTHOR), Gerstmann DR (AUTHOR), Labella JJ (AUTHOR), Sardesai S (AUTHOR), Walsh-Sukys MC (AUTHOR), McCaffrey MJ (AUTHOR), Cornfield DN (AUTHOR), Bhutani VK (AUTHOR), Cutter GR (AUTHOR), Baier M (AUTHOR), Abman SH (AUTHOR), Kinsella, J P (AUTHOR), Walsh, W F (AUTHOR), Bose, C L (AUTHOR), Gerstmann, D R (AUTHOR), Labella, J J (AUTHOR), Sardesai, S (AUTHOR), Walsh-Sukys, M C (AUTHOR)
Source: Lancet. 9/25/1999, Vol. 354 Issue 9184, p1061-1065. 5p.
Abstract: Background: Inhaled nitric oxide improves oxygenation and lessens the need for extracorporeal-membrane oxygenation in full-term neonates with hypoxaemic respiratory failure and persistent pulmonary hypertension, but potential adverse effects are intracranial haemorrhage and chronic lung disease. We investigated whether low-dose inhaled nitric oxide would improve survival in premature neonates with unresponsive severe hypoxaemic respiratory failure, and would not increase the frequency or severity of intracranial haemorrhage or chronic lung disease.Methods: We did a double-blind, randomised controlled trial in 12 perinatal centres that provide tertiary care. 80 premature neonates (gestational age < or = 34 weeks) with severe hypoxaemic respiratory failure were randomly assigned inhaled nitric oxide (n=48) or no nitric oxide (n=32, controls). Our primary outcome was survival to discharge. Analysis was by intention to treat. We studied also the rate and severity of intracranial haemorrhage, pulmonary haemorrhage, duration of ventilation, and chronic lung disease at 36 weeks' postconceptional age.Findings: The two groups did not differ for baseline characteristics or severity of disease. Inhaled nitric oxide improved oxygenation after 60 min (p=0.03). Survival at discharge was 52% in the inhaled-nitric-oxide group and 47% in controls (p=0.65). Causes of death were mainly related to extreme prematurity and were similar in the two groups. The two groups did not differ for adverse events or outcomes (intracranial haemorrhage grade 2-4, 28% inhaled nitric oxide and 33% control; pulmonary haemorrhage 13% and 9%; chronic lung disease 60% and 80%).Interpretation: Low-dose inhaled nitric oxide improved oxygenation but did not improve survival in severely hypoxaemic premature neonates. Low-dose nitric oxide in the most critically ill premature neonates does not increase the risk of intracranial haemorrhage, and may decrease risk of chronic lung injury. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 107081909
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kinsella+JP%22&quot;&gt;Kinsella JP&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walsh+WF%22&quot;&gt;Walsh WF&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bose+CL%22&quot;&gt;Bose CL&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gerstmann+DR%22&quot;&gt;Gerstmann DR&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Labella+JJ%22&quot;&gt;Labella JJ&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sardesai+S%22&quot;&gt;Sardesai S&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walsh-Sukys+MC%22&quot;&gt;Walsh-Sukys MC&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22McCaffrey+MJ%22&quot;&gt;McCaffrey MJ&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cornfield+DN%22&quot;&gt;Cornfield DN&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bhutani+VK%22&quot;&gt;Bhutani VK&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cutter+GR%22&quot;&gt;Cutter GR&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Baier+M%22&quot;&gt;Baier M&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Abman+SH%22&quot;&gt;Abman SH&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kinsella%2C+J+P%22&quot;&gt;Kinsella, J P&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walsh%2C+W+F%22&quot;&gt;Walsh, W F&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bose%2C+C+L%22&quot;&gt;Bose, C L&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gerstmann%2C+D+R%22&quot;&gt;Gerstmann, D R&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Labella%2C+J+J%22&quot;&gt;Labella, J J&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sardesai%2C+S%22&quot;&gt;Sardesai, S&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walsh-Sukys%2C+M+C%22&quot;&gt;Walsh-Sukys, M C&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 9/25/1999, Vol. 354 Issue 9184, p1061-1065. 5p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Inhaled nitric oxide improves oxygenation and lessens the need for extracorporeal-membrane oxygenation in full-term neonates with hypoxaemic respiratory failure and persistent pulmonary hypertension, but potential adverse effects are intracranial haemorrhage and chronic lung disease. We investigated whether low-dose inhaled nitric oxide would improve survival in premature neonates with unresponsive severe hypoxaemic respiratory failure, and would not increase the frequency or severity of intracranial haemorrhage or chronic lung disease.&lt;bold&gt;Methods: &lt;/bold&gt;We did a double-blind, randomised controlled trial in 12 perinatal centres that provide tertiary care. 80 premature neonates (gestational age &lt; or = 34 weeks) with severe hypoxaemic respiratory failure were randomly assigned inhaled nitric oxide (n=48) or no nitric oxide (n=32, controls). Our primary outcome was survival to discharge. Analysis was by intention to treat. We studied also the rate and severity of intracranial haemorrhage, pulmonary haemorrhage, duration of ventilation, and chronic lung disease at 36 weeks&#39; postconceptional age.&lt;bold&gt;Findings: &lt;/bold&gt;The two groups did not differ for baseline characteristics or severity of disease. Inhaled nitric oxide improved oxygenation after 60 min (p=0.03). Survival at discharge was 52% in the inhaled-nitric-oxide group and 47% in controls (p=0.65). Causes of death were mainly related to extreme prematurity and were similar in the two groups. The two groups did not differ for adverse events or outcomes (intracranial haemorrhage grade 2-4, 28% inhaled nitric oxide and 33% control; pulmonary haemorrhage 13% and 9%; chronic lung disease 60% and 80%).&lt;bold&gt;Interpretation: &lt;/bold&gt;Low-dose inhaled nitric oxide improved oxygenation but did not improve survival in severely hypoxaemic premature neonates. Low-dose nitric oxide in the most critically ill premature neonates does not increase the risk of intracranial haemorrhage, and may decrease risk of chronic lung injury. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=107081909
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(99)03558-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 1061
    Titles:
      – TitleFull: Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kinsella JP
      – PersonEntity:
          Name:
            NameFull: Walsh WF
      – PersonEntity:
          Name:
            NameFull: Bose CL
      – PersonEntity:
          Name:
            NameFull: Gerstmann DR
      – PersonEntity:
          Name:
            NameFull: Labella JJ
      – PersonEntity:
          Name:
            NameFull: Sardesai S
      – PersonEntity:
          Name:
            NameFull: Walsh-Sukys MC
      – PersonEntity:
          Name:
            NameFull: McCaffrey MJ
      – PersonEntity:
          Name:
            NameFull: Cornfield DN
      – PersonEntity:
          Name:
            NameFull: Bhutani VK
      – PersonEntity:
          Name:
            NameFull: Cutter GR
      – PersonEntity:
          Name:
            NameFull: Baier M
      – PersonEntity:
          Name:
            NameFull: Abman SH
      – PersonEntity:
          Name:
            NameFull: Kinsella, J P
      – PersonEntity:
          Name:
            NameFull: Walsh, W F
      – PersonEntity:
          Name:
            NameFull: Bose, C L
      – PersonEntity:
          Name:
            NameFull: Gerstmann, D R
      – PersonEntity:
          Name:
            NameFull: Labella, J J
      – PersonEntity:
          Name:
            NameFull: Sardesai, S
      – PersonEntity:
          Name:
            NameFull: Walsh-Sukys, M C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 09
              Text: 9/25/1999
              Type: published
              Y: 1999
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 354
            – Type: issue
              Value: 9184
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1